Diagnostic et prise en charge de la tumeur à cellules géantes ténosynoviale [Diagnosis and management of tenosynovial giant cell tumor]
Fiche du document
13 décembre 2023
- doi: 10.53738/REVMED.2023.19.854.2330
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.854.2330
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/38088403
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_E70F811661529
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2025-06-15 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Sciences de la gestion Gestion, Sciences de la Sciences de gestion Techniques de gestion Direction ManagementCiter ce document
C. Bakota-Morrison et al., « Diagnostic et prise en charge de la tumeur à cellules géantes ténosynoviale [Diagnosis and management of tenosynovial giant cell tumor] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.854.2330
Métriques
Partage / Export
Résumé
Tenosynovial giant cell tumor is a benign condition that originates from synovial cells within joints, tendon sheaths, or bursae and may present either in localized (benign) or diffuse (locally aggressive) forms. Currently, the primary treatment approach is surgical, yielding satisfactory results with low recurrence rates in the localized forms, whereas the diffuse type displays high recurrence rates. In parallel, clinical trials are underway to explore pharmaceutical treatment options for the advanced diffuse type. This article aims at consolidating current knowledge about diagnosis and management of this rare tumor, additionally proposing a brief overview of novel therapeutic approaches.